Literature DB >> 15333388

Xenon improves recovery from myocardial stunning in chronically instrumented dogs.

Maike A Grosse Hartlage1, Elmar Berendes, Hugo Van Aken, Manfred Fobker, Marc Theisen, Thomas P Weber.   

Abstract

In this study we tested the hypothesis that inhalational administration of xenon improves recovery from myocardial stunning. Ten dogs were chronically instrumented for measurement of heart rate; left atrial, aortic, and left ventricular pressure; coronary blood-flow velocity; and myocardial wall-thickening fraction. Regional myocardial blood flow was determined with fluorescent microspheres. Catecholamine plasma levels were measured by high-performance liquid chromatography. An occluder around the left anterior descending artery (LAD) allowed the induction of a reversible LAD ischemia. Animals underwent 2 experimental conditions in a randomized crossover fashion on separate days: (a) 10 min of LAD occlusion under fentanyl (25 microg. kg(-1). h(-1)) and midazolam (0.6 mg. kg(-1). h(-1)) (control) and (b) a second ischemic episode under the same basal anesthesia with concomitant inhalational administration of 75 +/- 1 vol% xenon (intervention). Anesthesia was induced 35 min before LAD occlusion and was discontinued after 20 min of reperfusion. Dogs receiving xenon showed a significantly better recovery of wall-thickening fraction up to 12 h after ischemia. The increase in plasma epinephrine during emergence from anesthesia and in the early reperfusion period was significantly attenuated in the xenon group. There were no differences between groups concerning global hemodynamics, blood-flow velocity, or regional myocardial blood flow. In conclusion, inhalational administration of 75 vol% xenon improves recovery from myocardial stunning in chronically instrumented dogs under fentanyl/midazolam anesthesia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15333388     DOI: 10.1213/01.ANE.0000129999.74324.4E

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  7 in total

1.  Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in a rat model of thromboembolic stroke.

Authors:  Hélène N David; Benoît Haelewyn; Jean-Jacques Risso; Nathalie Colloc'h; Jacques H Abraini
Journal:  J Cereb Blood Flow Metab       Date:  2010-01-20       Impact factor: 6.200

2.  Xenon triggers pro-inflammatory effects and suppresses the anti-inflammatory response compared to sevoflurane in patients undergoing cardiac surgery.

Authors:  Thomas Breuer; Christoph Emontzpohl; Mark Coburn; Carina Benstoem; Rolf Rossaint; Gernot Marx; Gereon Schälte; Juergen Bernhagen; Christian S Bruells; Andreas Goetzenich; Christian Stoppe
Journal:  Crit Care       Date:  2015-10-15       Impact factor: 9.097

3.  Xenon protects left ventricular diastolic function during acute ischemia, less than ischemic preconditioning.

Authors:  Jan-H Baumert; Anna B Roehl; Sandra Funcke; Marc Hein
Journal:  Med Gas Res       Date:  2016-10-14

4.  The Modification and Performance of a Large Animal Anesthesia Machine (Tafonius®) in Order to Deliver Xenon to a Horse.

Authors:  Bruna Santangelo; Astrid Robin; Keith Simpson; Julie Potier; Michel Guichardant; Karine Portier
Journal:  Front Vet Sci       Date:  2017-09-29

5.  Evaluation of hemodynamic effects of xenon in dogs undergoing hemorrhagic shock.

Authors:  Ruben C Franceschi; Luiz Malbouisson; Eduardo Yoshinaga; Jose Otavio Costa Auler; Luiz Francisco Poli de Figueiredo; Maria Jose C Carmona
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

6.  Xenon treatment protects against cold ischemia associated delayed graft function and prolongs graft survival in rats.

Authors:  H Zhao; H R Watts; M Chong; H Huang; C Tralau-Stewart; P H Maxwell; M Maze; A J T George; D Ma
Journal:  Am J Transplant       Date:  2013-05-24       Impact factor: 8.086

Review 7.  Update of the organoprotective properties of xenon and argon: from bench to beside.

Authors:  Roehl Anna; Rossaint Rolf; Coburn Mark
Journal:  Intensive Care Med Exp       Date:  2020-02-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.